Relypsa Inc Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2021-11-03: Study NCT04903717; Company role Collaborator; Phase Not applicable; Status Completed.
- 2018-07-17: Study NCT03597035; Company role Collaborator; Phase Phase 4; Status Terminated.
- 2017-01-23: Study NCT03071263; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2016-09: Study NCT02823626; Company role Collaborator; Phase Observational; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2021-11-03 | NCT04903717 Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists | Collaborator Lead: Yale University | Not applicable | Completed | Heart Failure With Reduced Ejection Fraction | 1,210 | 2024-02-06 |
| 2018-07-17 | NCT03597035 Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On | Collaborator Lead: University Hospitals Cleveland Medical Center | Phase 4 | Terminated Results posted | Type2 Diabetes; Hyperkalemia | 8 | 2020-07-31 |
| 2017-01-23 | NCT03071263 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease | Lead sponsor | Phase 2 | Completed Results posted | Hyperkalemia; Resistant Hypertension | 295 | 2018-11-27 |
| 2016-09 | NCT02823626 High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure | Collaborator Lead: The University of Texas Health Science Center at San Antonio | Observational | Completed | Acute Decompensated Heart Failure | 48 | 2018-04 |
| 2016-08 | NCT02933450 Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE) | Collaborator Lead: Baylor College of Medicine | Phase 4 | Completed Results posted | Kidney Failure, Chronic | 43 | 2017-08 |
| 2016-07 | NCT02842957 An Intensive Lifestyle Intervention Program in CKD (Move to Health 2) | Collaborator Lead: Springfield College | Not applicable | Completed | Kidney Disease | 42 | 2017-04-08 |
| 2016-02 | NCT02694744 Patiromer With or Without Food for the Treatment of Hyperkalemia | Lead sponsor | Phase 4 | Completed Results posted | Hyperkalemia | 114 | 2016-08 |
| 2013-02 | NCT01810939 A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) | Lead sponsor | Phase 3 | Completed Results posted | Chronic Kidney Disease (CKD); Hyperkalemia (HK) | 243 | 2013-08 |
| 2011-06 | NCT01371747 Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) | Lead sponsor | Phase 2 | Completed Results posted | Chronic Kidney Disease; Hypertension; Hyperkalemia | 324 | 2013-06 |
| 2010-05 | NCT01130597 Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease | Lead sponsor | Phase 2 | Completed Results posted | Heart Failure | 63 | 2010-09 |
| 2009-04 | NCT00868439 Evaluation of Patiromer in Heart Failure Patients | Lead sponsor | Phase 2 | Completed Results posted | Hyperkalemia; Heart Failure | 120 | 2009-12 |
| 2008-08 | NCT02033317 An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis | Lead sponsor | Phase 2 | Terminated Results posted | Hyperkalemia | 6 | 2008-12 |